BACKGROUND: As a type of malignant tumor, head and neck squamous cell carcinoma (HNSCC) seriously threatens human health. This study is aimed at constructing a new, reliable prognostic model. METHOD: The gene expression profile data of HNSCC patients were downloaded from the Gene Expression Omnibus and The Cancer Genome Atlas databases. The immune-related differentially expressed genes (IRDEGs) related to HNSCC were identified. We then used Cox regression analysis and least absolute shrinkage and selection operator (LASSO) analysis to explore IRDEGs related to the HNSCC prognosis and to construct and validate a risk scoring model and used ESTIMATE to evaluate tumor immune infiltration in HNSCC patients. Finally, we validated IGSF5 expression and function in HNSCC cells. RESULTS: A total of 1,195 IRDEGs were found from the GSE65858 dataset. Thirty-one of the 1,195 IRDEGs were associated with the prognosis of HNSCC. Nine key IRDEGs were further selected using the LASSO method, and a risk scoring model was established for predicting the survival of HNSCC patients. According to the risk scoring model, the prognosis of patients in the high-risk group was worse than that of the low-risk group; the high-risk group had significantly higher immune scores than the low-risk group; and between the high- and low-risk samples, there were significant differences in the proportion of 10 types of cells, including naive cells, plasma cells, and resting CD4+ memory T cells. IGSF5 has low expression in HNSCC, and overexpression of IGSF5 significantly impaired HNSCC cell proliferation. CONCLUSION: This prognostic risk assessment model can help systematically evaluate the survival prognosis of HNSCC patients and provides a new research direction for the improvement of the survival prognosis of HNSCC patients in clinical practice.
BACKGROUND: As a type of malignant tumor, head and neck squamous cell carcinoma (HNSCC) seriously threatens human health. This study is aimed at constructing a new, reliable prognostic model. METHOD: The gene expression profile data of HNSCC patients were downloaded from the Gene Expression Omnibus and The Cancer Genome Atlas databases. The immune-related differentially expressed genes (IRDEGs) related to HNSCC were identified. We then used Cox regression analysis and least absolute shrinkage and selection operator (LASSO) analysis to explore IRDEGs related to the HNSCC prognosis and to construct and validate a risk scoring model and used ESTIMATE to evaluate tumor immune infiltration in HNSCC patients. Finally, we validated IGSF5 expression and function in HNSCC cells. RESULTS: A total of 1,195 IRDEGs were found from the GSE65858 dataset. Thirty-one of the 1,195 IRDEGs were associated with the prognosis of HNSCC. Nine key IRDEGs were further selected using the LASSO method, and a risk scoring model was established for predicting the survival of HNSCC patients. According to the risk scoring model, the prognosis of patients in the high-risk group was worse than that of the low-risk group; the high-risk group had significantly higher immune scores than the low-risk group; and between the high- and low-risk samples, there were significant differences in the proportion of 10 types of cells, including naive cells, plasma cells, and resting CD4+ memory T cells. IGSF5 has low expression in HNSCC, and overexpression of IGSF5 significantly impaired HNSCC cell proliferation. CONCLUSION: This prognostic risk assessment model can help systematically evaluate the survival prognosis of HNSCC patients and provides a new research direction for the improvement of the survival prognosis of HNSCC patients in clinical practice.
Authors: Wenbo Ma; Fernando Concha-Benavente; Saskia J A M Santegoets; Marij J P Welters; Ilina Ehsan; Robert L Ferris; Sjoerd H van der Burg Journal: PLoS One Date: 2018-09-07 Impact factor: 3.240
Authors: Axel Lechner; Hans A Schlößer; Martin Thelen; Kerstin Wennhold; Sacha I Rothschild; Ramona Gilles; Alexander Quaas; Oliver G Siefer; Christian U Huebbers; Engin Cukuroglu; Jonathan Göke; Axel Hillmer; Birgit Gathof; Moritz F Meyer; Jens P Klussmann; Alexander Shimabukuro-Vornhagen; Sebastian Theurich; Dirk Beutner; Michael von Bergwelt-Baildon Journal: Oncoimmunology Date: 2019-01-10 Impact factor: 8.110
Authors: Eloy F Robles; Maria Mena-Varas; Laura Barrio; Sara V Merino-Cortes; Péter Balogh; Ming-Qing Du; Takashi Akasaka; Anton Parker; Sergio Roa; Carlos Panizo; Idoia Martin-Guerrero; Reiner Siebert; Victor Segura; Xabier Agirre; Laura Macri-Pellizeri; Beatriz Aldaz; Amaia Vilas-Zornoza; Shaowei Zhang; Sarah Moody; Maria Jose Calasanz; Thomas Tousseyn; Cyril Broccardo; Pierre Brousset; Elena Campos-Sanchez; Cesar Cobaleda; Isidro Sanchez-Garcia; Jose Luis Fernandez-Luna; Ricardo Garcia-Muñoz; Esther Pena; Beatriz Bellosillo; Antonio Salar; Maria Joao Baptista; Jesús Maria Hernandez-Rivas; Marcos Gonzalez; Maria Jose Terol; Joan Climent; Antonio Ferrandez; Xavier Sagaert; Ari M Melnick; Felipe Prosper; David G Oscier; Yolanda R Carrasco; Martin J S Dyer; Jose A Martinez-Climent Journal: Nat Commun Date: 2016-06-14 Impact factor: 14.919
Authors: Stefano Cavalieri; Mara S Serafini; Andrea Carenzo; Silvana Canevari; Ruud H Brakenhoff; C René Leemans; Irene H Nauta; Frank Hoebers; Mari F C M van den Hout; Kathrin Scheckenbach; Thomas K Hoffmann; Laura Ardighieri; Tito Poli; Pasquale Quattrone; Laura D Locati; Lisa Licitra; Loris De Cecco Journal: JCO Precis Oncol Date: 2021-10-27
Authors: Anna Tosi; Beatrice Parisatto; Paolo Boscolo-Rizzo; Antonio Rosato; Anna Menegaldo; Giacomo Spinato; Maria Guido; Annarosa Del Mistro; Rossana Bussani; Fabrizio Zanconati; Margherita Tofanelli; Giancarlo Tirelli Journal: J Exp Clin Cancer Res Date: 2022-09-20